InsidersTradesSigma
Explore the full insider trade history of ARATANA THERAPEUTICS, INC., a publicly traded company based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was filed on 2 February 2016 (Cession). Among the most active insiders: TOOMAN CRAIG A. Every trade is accessible without an account.
Analysts rate ARATANA THERAPEUTICS, INC. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
5 of 5 declarations
ARATANA THERAPEUTICS, INC. is a biopharmaceutical company focused on developing therapeutic products for companion animals. The company is listed on NASDAQ under the ticker symbol PETX.